New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer
-
Narrated by:
-
By:
About this listen
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three major updates in oncology. Vimseltinib (Romvimza) has been FDA-approved for tenosynovial giant cell tumors (TGCT), providing a new non-surgical option for symptomatic patients. Sotorasib plus panitumumab is now approved for KRAS G12C-mutated colorectal cancer, marking a breakthrough in targeted therapy for this hard-to-treat population. Finally, two phase III trials show that adding immunotherapy to neoadjuvant chemotherapy improves pathological complete response rates in high risk ER positive, HER2 negative breast cancer—a potential paradigm shift in treatment. Tune in for the latest updates in precision oncology!